Phase II trial with weekly cisplatin (CDDP) and continously oral etoposide (VP-16) in advanced non-small cell lung cancer (NSCLC) - European Journal of Cancerdoi:10.1016/0959-8049(93)91521-LLopez, R.Fernandez, R.Virizuela, J.A.
Concurrent platinum (CDDP)-etoposide (VP-16) chemotherapy plus thoracic radiotherapy (TRT) for limited stage small cell lung cancer (SCLC) : N. Saijo, M. Fukuoka, K. Furuse, Y. Ariyoshi, Y. Nishiwaki, H. Ikegami, M. Oritsu A Japanese Lung Cancer Chemotherapy Group (JLCCG) study, ...
Results of Cisplatin (CDDP)/Etoposide (VP16)/5-FU and alternatively Adriamycin or Mitomycin C (PEFAM) combination in primary resistant breast cancer and in heavily pre-treated metastatic breast cancerIn spite of the activity of chemotherapeutic agents, metastatic breast cancer remains an incurable ...
Clinical evaluation of adjuvant chemoradiotherapy with CDDP, 5-Fu, and VP-16 for advanced esophageal cancer. Jpn J Thorac Cardiovasc Surg. 1998;46:11-7.Mukaida H, Hirai T, Yamashita Y, Yoshida K, Hihara J, Kuwahara M, et al. Clinical evaluation of adjuvant chemoradiotherapy with CDDP, 5-...
应用Navelbine(NVB)与Cis-platinum(CDDP)组合,进行对肺腺癌治疗的临床观察,并与临床常用方案Etoposide(VP-16)Cis-platinum(CDDP)对照观察如下.1 材料与方法1 1 病例选择全部病例106例,随机分为A,B两组,各53例.条件为:1)非手术肺腺癌患者;2)有病理/细胞学及X线(CT,MRI)诊断;3)无重度心,肝,肾及骨髓功能...
Madrigal PA, Manga GP, Palomero I, Gomez RG. VP16-213 combined with cis-platinum (CDDP) in the treatment of small cell carcinoma of the lung (SCLC). Cancer Chemother Pharmacol. 1982; 7 (2-3):203–204.Madrigal PA, Manga GP, Palomero I, et al: VP16-213 combined with cis-platinum ...
目的:探讨拓扑替康(Topotecan,TPT)及联合化疗对卵巢癌细 胞系的治疗效果.方法:将TPT单用或与3种临床上常用的卵巢上皮癌化疗药物顺铂(cDDP),卡铂(CBP),VP-16合用,观察人卵巢上皮癌 (OEC)细胞系3AO及其顺铂耐药细胞系3AO/cDDP的生长抑制率及耐药指数,药物敏感试验采用MTT法.结果:3AO对cDDP最为敏感 (P<0.01)...
Response rate in advanced soft tissue sarcoma using cisplatin (CDDP), adriamycin, and VP16An abstract is unavailable. This article is available as a PDF only.doi:10.1097/00043426-199123000-00031E. G. AntoneliR. MelaragnoL. A. Marques
Accelerated hyperfractionated thoracic radiation therapy plus concomitant VP16-CDDP chemotherapy for unresectable stage III non-small cell lung cancerShaw, E. G.McGinnis, W.Jett, J.Su, J.LUNG CANCER -AMSTERDAM-
CDDP-resistant (SBC-3/CDDP) and VP16-resistant (SBC-3/VP16) small cell lung cancer(SCLC) cells show a unique collateral sensitivity in culture : Taisuke OHNOSHI, Hiroshi UEOKA, Katsuyuki KIURA, Nagio TAKIGAWA and Ikuro KIMURA Department of Medicine, Okayama University Medical School, Okayama...